Application of the New McDonald Criteria to Patients with Clinically Isolated Syndromes Suggestive of Mulitple Sclerosis
Ann Neurol 52:47-53, Dalton,C.M.,et al, 2002
Early Symptom Progression Rate is Related to ALS Outcome
Neurol 59:99-103, Chio,A.,et al, 2002
Migraine--Current Understanding and Treatment
NEJM 346:257-270, Goadsby,P.J.,et al, 2002
Refractory Status Epilepticus
Arch Neurol 59:205-210,188, Mayer,S.A.,et al, 2002
An Open-Label Trial of Combination Therapy With Interferon B-1a and Oral Methotrexate in MS
Neurol 58:314-317, Calabresi,P.A.,et al, 2002
Disease Modifying Therapies in Multiple Sclerosis
Neurol 58:169-178, Goodin,D.S.,et al, 2002
A Longitudinal Study of Abnormalities on MRI and Disability From Multiple Sclerosis
NEJM 346:158-164,199, Brex,P.A.,et al, 2002
Plasma Exchange for Severe Attacks of CNS: Demyelination: Predictors of Response
Neurol 58:143-146, Keegan,M.,et al, 2002
Predictors of Functional Disability and Mortality After Status Epilepticus
Neurol 58:139-142, Claassen,J.,et al, 2002
Patients with Multiple Sclerosis and Risk of Type 1 Diabetes Mellitus in Sardinia,Italy: A Cohort Study
Lancet 359:1461-1465,1450, Marrosu,M.G.,et al, 2002
Efficacy and Safety of Modafinil (Provigil) for the Treatment of Fatigue in Multiple Sclerosis: A Two Centre Phase 2 Study
JNNP 72:179-183,150, Rammohan,K.W.,et al, 2002
Differentiation of Multiple Sclerosis from Other Inflammatory Disorders and Cerebrovascular Disease: Value of Spinal MR Imaging
Radiology 223:46-56, Bot,J.C.J.,et al, 2002
Results of Radiotherapy for Drooling in Amyotrophic Lateral Sclerosis
Neurol 58:1308, Stalpers,L.J.A. &Moser,E.C., 2002
Interferon Beta-1a for Early Multiple Sclerosis: CHAMPS Trial Subgroup Analyses
Ann Neurol 51:481-490, Beck,R.W.,et al, 2002
Clinicopath Conf, Hyperviscosity Syndrome Due to IgG Multiple Myeloma
NEJM 346:603-610, Case 6-2002, 2002
Familial Amyotrophic Lateral Sclerosis
Muscle Nerve 25:135-159, Hand,C.K. &Rouleau,G.A., 2002
Sandlike Appearance of Virchow-Robin Spaces in Early Multiple Sclerosis:A Novel Neuroradiologic Marker
AJNR 23:376-380, Achiron,A.&Faibel,M., 2002
Recent Developments in Neurology
BMJ 324:656-660, Wiebe,S.,&Nicolle,M.W., 2002
Multiple Sclerosis
Lancet 359:1221-1231, Compston,A. &Coles,A., 2002
Safety, Tolerability, and Efficacy of Orally Administered Cannabinoids in MS
Neurol 58:1404-1407,1323, Killestein,J.,et al, 2002
Disease-Modifying Therapy in Multiple Sclerosis: Strategies for Optimizing Management
The Neurologist 8:227-236, Frohman,E.,et al, 2002
Outcome of and Prognostic Factors for Herpes Simplex Encephalitis in Adult Patients: Results of a Multicenter Study
Clin Inf Dis 35:254-260, Raschillas, F.,et al, 2002
Epstein-Barr Virus Antibodies and Risk of Multiple Sclerosis
JAMA 286:3083-3088,3127, Ascherio,A.,et al, 2001
Scleroderma "En Coup De Sabre":Pathological Evidence of Intracerebral Inflammation
JNNP 70:382-385, Stone,J.,et al, 2001
Systematic Review of Immunomodulatory Drugs for the Treatment of People with Multiple Sclerosis: Is There Good Quality Evidence on Effectiveness and Cost?
JNNP 70:574-579, Bryan,J.,et al, 2001
Problems With Diagnositc Criteria for Multiple Sclerosis
Lancet 358:1746-1747, Poser,C.M. &Brinar,V.V., 2001
Surgical Therapy for Tremor in Multiple Sclerosis
Neurol 57:1876-1882, Matsumoto,J.,et al, 2001
Improved Accuracy of Clinical Diagnosis of Lewy Body Parkinson's Disease
Neurol 57:1497-1499, Hughes,A.J.,et al, 2001
Oligoclonal Band Number as a Marker for Prognosis in Multiple Sclerosis
Arch Neurol 58:2044-2045, Avasarala,J.R.,et al, 2001
Isolated Demyelinating Syndromes: Comparison of CSF Oligoclonal Bands and Different MR Imaging Criteria to Predict Conversion to CDMS
Mult Scler 7:359-363, Tintore,M.,et al, 2001
Linear Pontine Trigeminal Root Lesions in Multiple Sclerosis
Arch Neurol 58:101-104, Nakashima,I.,et al, 2001
Multiple Sclerosis and Magnetic Resonance Imaging
Arch Neurol 58:35-36, Racke,M.K.,et al, 2001
Cerebellar Ataxia With Anti-Glutamic Acid Decarboxylase Antibodies
Arch Neurol 58:225-230, Honorat,J.,et al, 2001
APOE Genotype is a Major Predictor of Long-Term Progression of Disability in MS
Neurol 56:312-316, Chapman,J.,et al, 2001
Hepatitis B Vaccination and the Risk of Multiple Sclerosis
NEJM 344:327-332,372,381, Ascherio,A.,et al, 2001
Vaccinations and the Risk of Relapse in Multiple Sclerosis
NEJM 344:319-326,372, Confavreux,C.,et al, 2001
Positive Response to Immunommodulatory Therapy in an Adult Patient with Rasmussen's Encephalitis
Neurol 56:248-250, Villani,F.,et al, 2001
Clinicopath Conf,Invasive Fungal Sinusitis & Osteomyelitis Due to Mucormycosis
NEJM 344:286-293, Case 3-2001, 2001
Sudden Sensorineural Hearing Loss Associated with Herpes Simplex Virus Type 1 Infection
Neurol 56:571-572, Rabinstein,A.,et al, 2001
Assessing the Risk of Early Multiple Sclerosis in Patients with Clinically Isolated Syndromes: the Role of a Follow Up MRI
JNNP 70:390-393, Brex,P.A.,et al, 2001
Handicap After Acute Whiplash Injury
Neurol 56:1637-1643, Kasch,H.,et al, 2001
Return to Driving After Head Injury
JNNP 70:761-766, Hawley,C.A., 2001
Acute Motor Radiculopathy as a First Symptom of MS: Anatomic-radiologic Correlation
Neurol 56:1603-1604, Lavallee,P.,et al, 2001
A Longitudinal MRI Study of Histopathologically Defined Hypointense Multiple Sclerosis Lesions
Ann Neurol 49:793-796, Bitsch,A.,et al, 2001
Autologous Hematopoietic Stem Cell Transplantation Suppresses Gd-enhanced MRI activity in MS
Neurol 57:62-68, Mancardi,G.L.,et al, 2001
A Three-item Scale for the Early Prediction of Stroke Recovery
Lancet 357:2095-2099, Baird,A.E.,et al, 2001
PRISMS-4: Long-Term Efficacy of Interferon-B-1a in Relapsing MS
Neurol 56:1628-1636,1620, The PRISMS Study Group, 2001
Measurement of Antibodies to Interferon Beta in Patients With Multiple Sclerosis
Arch Neurol 58:1299-1300,1301, Pachner,A.R., 2001
The Significance of Neutralizing Antibodies in Patients With Multiple Sclerosis Treated With Interferon Beta
Arch Neurol 58:1297-1298,1301, Rice,G., 2001
Inclusiong Body Myositis Mimicking Motor Neuron Disease
Arch Neurol 58:1253-1256, Dabby,R.,et al, 2001